The thioredoxin system: A key target in tumour and endothelial cells

British Journal of Radiology

Volumn 81, Issue SPECIAL ISSUE, 2008, Pages

  Mukherjee, A ^a   Martin, S G ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BW 114; GADOLINIUM TEXAPHYRIN; NCS 645300; NSC 140377; NSC 645300; PLEUROTIN; PMX 464; PROTEIN INHIBITOR; PX 12; PX 916; THIOREDOXIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER TISSUE; CELL CYCLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DETERMINATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SCREENING; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; APOPTOSIS; BENZOTHIAZOLES; CATTLE; CYCLOHEXANONES; DISULFIDES; ENDOTHELIAL CELLS; HUMANS; HYDROQUINONES; HYPOXIA-INDUCIBLE FACTOR 1; IMIDAZOLES; NEOPLASMS; THIOREDOXINS; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55449130109     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/34180435     Document Type: Conference Paper

References (104)

1. Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 2004;30:421-55.
2. Gromer S, Urig S, Becker K. The thioredoxin system - from science to clinic. Med Res Rev 2004;24:40-89.
3. Laurent TC, Moore EC, Reichard P. Enzymatic synthesis of deoxyribonucleotides. IV. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia Coli B. J Biol Chem 1964;239:3436-44.
4. Luthman M, Holmgren A. Rat liver thioredoxin and thioredoxin reductase: purification and characterization. Biochemistry 1982;21:6628-33.
5. Mustacich D, Powis G. Thioredoxin reductase. Biochem J 2000;346 Pt 1:1-8.
6. Gasdaska PY, Gasdaska JR, Cochran S, Powis G. Cloning and sequencing of a human thioredoxin reductase. FEBS Lett 1995;373:5-9.
7. Gasdaska PY, Berggren MM, Berry MJ, Powis G. Cloning, sequencing and functional expression of a novel human thioredoxin reductase. FEBS Lett 1999;442:105-11.
8. Pedrajas JR, Kosmidou E, Miranda-Vizuete A, Gustafsson JA, Wright AP, Spyrou G. Identification and functional characterization of a novel mitochondrial thioredoxin system in Saccharomyces cerevisiae. J Biol Chem 1999;274:6366-73.
9. Cheng GC, Schulze PC, Lee RT, Sylvan J, Zetter BR, Huang H. Oxidative stress and thioredoxin-interacting protein promote intravasation of melanoma cells. Exp Cell Res 2004;300:297-307.
10. Schallreuter KU, Wood JM. Thioredoxin reductase - its role in epidermal redox status. J Photochem Photobiol B 2001;179-84.
11. Fernando MR, Nanri H, Yoshitake S, Nagata-Kuno K, Minakami S. Thioredoxin regenerates proteins inactivated by oxidative stress in endothelial cells. Eur J Biochem 1992;209:917-22.
12. Kahlos K, Zhang J, Clock ER, Patel JM. Thioredoxin restores nitric oxide-induced inhibition of protein kinase C activity in lung endothelial cells. Mol Cell Biochem 2003;254:47-54.
13. Anema SM, Walker SW, Howie AF, Arthur JR, Nicol F, Beckett GJ. Thioredoxin reductase is the major selenoprotein expressed in human umbilical-vein endothelial cells and is regulated by protein kinase C. Biochem J 1999;342:111-17.
14. Yamada Y Nakamura H, Adachi T, Sannohe S, Oyamada H, Kayaba H, et al. Elevated serum levels of thioredoxin in patients with acute exacerbation of asthma. Immunol Lett 2003;86:199-205.
15. Soini Y, Kaarteenana-Wiik R, Paakko P, Kinnula V. Expression of antioxidant enzymes in bronchial metaplastic and dysplastic epithelium. Lung Cancer 2003;39:15-22.
16. Soini Y, Kahlos K, Napankangas U, Kaarteenaho-Wiik R, Säily M, Koistinen P, et al. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 2001;7:1750-7.
17. Lichtenfels R, Kellner R, Atkins D, Bukur J, Ackermann A, Beck J, et al. Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta 2003;1646:21-31.
18. Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res 2003;23:2425-33.
19. Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, Alberts DS, et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 2003;142:46-51.
20. Park JH, Kim YS, Lee HL, Shim JY, Lee KS, Oh YJ, et al. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology 2006;11:269-75.
21. Jarvela S, Bragge H, Paunu N, Järvelä T, Padjärvi L, Kalimo H, et al. Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival. J Neurooncol 2006;77:131-40.
22. Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M, et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 1995;55:4293-6.
23. Sasada T, Nakamura H, Ueda S, Sato N, Kitaoka Y, Gon Y, et al. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic Biol Med 1999;27(5-6):504-14.
24. Surowiak P, Materna V, Kaplenko I, Spaczyński M, Dietel M, Lage H, et al. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch 2005;447:626-33.
25. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005;23:422-31.
26. Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y, Nakamura H, Yodoi J, et al. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res 2005;11:8425-30.
27. Tome ME, Johnson DB, Rimsza LM, Roberts RA, Grogan TM, Miller TP, et al. A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. Blood 2005;106:3594-601.
28. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102:673-8.
29. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, et al. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappa B. J Biol Chem 1999;274:27891-7.
30. Schenk H, Klein M, Erdbrugger W, Droge W, Schulze-Osthoff K. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. Proc Natl Acad Sci U S A 1994;91:1672-6.
31. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, Hay RT. Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res 1992;20:3821-30.
32. Arlt A, Schafer H. NFkappaB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther 2002Aug;40(8):336-47.
33. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A 1997;94:3633-8.
34. Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, et al. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 1999;274:35809-15.
35. Makino Y, Yoshikawa N, Okamoto KY, Aoshima M, Hirota K, Yodoi J, et al. Thioredoxin: a redox-regulating cellular cofactor or glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. J Clin Invest 1996;98:2469-77.
36. Hayashi S, Hajiro-Nakanishi K, Makino Y, Eguchi H, Yodoi J, Tanaka H. Functional modulation of estrogen receptor by redox state with reference to thioredoxin as a mediator. Nucleic Acids Res 1997;25:4035-40.
37. U-Taniguchi Y, Furuke K, Masutani H, Nakamura H, Yodoi J. Cell cycle inhibition of HTLV-I transformed T cell lines by retinoic acid: the possible therapeutic use of thioredoxin reductase inhibitors. Oncol Res 1995;7:183-9.
38. Khan IA, Luduena RF. Possible regulation of the in vitro assembly of bovine brain tubulin by the bovine thioredoxin system. Biochim Biophys Acta 1991;1076:289-97.
39. Sadek CM, Jimenez A, Damdimopoulos AE, Kieselbach T, Nord M, Gustafsson JA, et al. Characterization of human thioredoxin-like 2. A novel microtubule-binding thioredoxin expressed predominantly in the cilia of lung airway epithelium and spermatid manchette and axoneme. J Biol Chem 2003;278:13133-42.
40. Moon MS, Kim JS, Kim TL, Yum JJ, Cho EW, Kim IG. Polyamine depletion partially reduces the radiation-induced cell death via cell cycle delay mediated by thioredoxin. Cell Biol Toxicol 2006;22:137-47.
41. Landino LM, Skreslet TE, Alston JA. Cysteine oxidation of tau and microtubule-associated protein-2 by peroxynitrite: modulation of microtubule assembly kinetics by the thioredoxin reductase system. J Biol Chem 2004;279:35101-5.
42. Baker A, Payne CM, Briehl MM, Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res 1997;57:5162-7.
43. Zhang P, Liu B, Kang SW, Seo MS, Rhee SG, Obeid LM. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J Biol Chem 1997;272:30615-18.
44. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998;17:2596-606.
45. Nonn L, Berggren MM, Powis G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res 2003;1:682-9.
46. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 1996;16:3459-66.
47. Kim HJ, Chae HZ, Kim YJ, Kim YH, Hwangs TS, Park EM, et al. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol 2003;19:285-98.
48. Hedley D, Pintilie M, Woo J, Nicklee T, Morrision A, Birle D, et al. Up-regulation of the redox mediators thioredoxin and apurinic/apyrimidinic excision (APE)/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis. Am J Pathol 2004;164:557-65.
49. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1a protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 2002;62:5089-95.
50. Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K, et al. Molecular mechanisms of transcription activation by HLF and HIF1a in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 1999;18:1905-14.
51. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
52. Meuillet EJ, Mahadevan D, Berggren M, Coon A, Powis G. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch Biochem Biophys 2004;429:123-33.
53. Jones DT, Pugh CW, Wigfield S, Stevens MF, Harris AL. Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation. Clin Cancer Res 2006;12:5384-94.
54. Kim WJ, Cho H, Lee SW, Kim YJ, Kim KW. Antisense-thioredoxin inhibits angiogenesis via pVHL-mediated hypoxia-inducible factor-1α degradation. Int J Oncol 2005;26:1049-52.
55. Csiki I, Yanagisawa K, Haruki N, Nadaf S, Morrow JD, Johnson DH, et al. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. Cancer Res 2006;66:143-50.
56. Zhou J, Damdimopoulos AE, Spyrou G, Brune B. Thioredoxin 1 and Thioredoxin 2 have opposed regulatory functions on hypoxia-inducible factor-1{alpha}. J Biol Chem 2007;282:7482-90.
57. Farina AR, Tacconelli A, Cappabianca L, DeSantis G, Gulino A, Mackay AR. Thioredoxin inhibits microvascular endothelial capillary tubule formation. Exp Cell Res 2003;291:474-83.
58. Farina AR, Tacconelli A, Cappabianca L, Masciulli MP, Holmgren A, Beckett GJ, et al. Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion. Eur J Biochem 2001;268:405-13.
59. Le Jan S, Le Meur N, Cazes A, Philippe J, Le Cunff M, Léger J, et al. Characterization of the expression of the hypoxia-induced genes neuritin, TXNIP and IGFBP3 in cancer. FEBS Lett 2006;580:3395-400.
60. Ng M, Wu J, Chang E, Wang BJ, Katzenberg-Clark R, Ishii-Watabe A, et al. A central role for nicotinic cholinergic regulation of growth factor induced endothelial cell migration. Arterioscler Thromb Vasc Biol 2007;27:106-112.
61. Schallreuter KU, Pittelkow MR. Anthralin inhibits elevated levels of thioredoxin reductase in psoriasis. A new mode of action for this drug. Arch Dermatol 1987;123:1494-8.
62. Schallreuter KU, Wood JM. Thioredoxin reductase in control of the pigmentary system. Clin Dermatol 1989;7:92-105.
63. Wurfel M, Haberlein I, Follmann H. Inactivation of thioredoxin by sulfite ions. FEBS Lett 1990;268:146-8.
64. Schallreuter KU, Gleason FK, Wood JM. The mechanism of action of the nitrosourea anti-tumor drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase. Biochim Biophys Acta 1990;1054:14-20.
65. Mau BL, Powis G. Mechanism-based inhibition of thioredoxin reductase by antitumor quinoid compounds. Biochem Pharmacol 1992;43:1613-20.
66. Gromer S, Arscott LD, Williams CH Jr, Schirmer RH, Becker K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 1998;273:20096-101.
67. Nordberg J, Zhong L, Holmgren A, Arner ES. Mammalian thioredoxin reductase is irreversibly inhibited by dinitro-halobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue. J Biol Chem 1998;273:10835-42.
68. Ishikawa A, Kubota Y, Murayama T, Nomura Y. Cell death by 1-chloro-2,4-dinitrobenzene, an inhibitor of thioredoxin reductase and its dual regulation by nitric oxide in rats. Neurosci Lett 1999;277:99-102.
69. Sugimoto M, Inoue T, Takeshita K, Nakamura H, Yodoi J. Effects of a new anti-rheumatic drug KE-298 and its active metabolite: KE-758 on secretion of thioredoxin and on the level of intracellular glutathione in human monocytes and T cells. Mol Immunol 2002;38:793-9.
70. Becker K, Herold-Mende C, Park JJ, Lowe G, Schirmer RH. Human thioredoxin reductase is efficiently inhibited by (2,2′:6′,2′ '-terpyridine) platinum(II) complexes. Possible implications for a novel antitumor strategy. J Med Chem 2001;44:2784-92.
71. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 2002;99:11700-5.
72. Rigobello MP, Scutari G, Folda A, Bindoli A. Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c. Biochem Pharmacol 2004;67:689-96.
73. Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003;21:2529-36.
74. Engman L, Cotgreave I, Angulo M, Taylor CW, Paine-Murrieta GD, Powis G. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents. Anticancer Res 1997;17:4599-605.
75. Kirkpatrick DL, Kuperus M, Dowdeswell M, Potier N, Donald LJ, Kunkel M, et al. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol 1998;55:987-94.
76. Lee YJ, Kim JH, Chen J, Song JJ. Enhancement of metabolic oxidative stress-induced cytotoxicity by the thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disulfide is mediated through the ASK1-SEK1-JNK1 pathway. Mol Pharmacol 2002;62:1409-17.
77. Wells G, Berry JM, Bradshaw TD, Burger AM, Seaton A, Wang B, et al. 4-Substituted 4-hydroxycyclohexa-2,5-dien-1-ones with selective activities against colon and renal cancer cell lines. J Med Chem 2003;46:532-41.
78. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1a and vascular endothelial growth factor formation. Mol Cancer Ther 2003;2:235-43.
79. Powis G, Wipf P, Lynch SM, Birmingham A, Kirkpatrick DL. Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase. Mol Cancer Ther 2006;5:630-6.
80. Wipf P, Hopkins TD, Jung JK, Rodriguez S, Birmingham A, Southwick EC, et al. New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead. Bioorg Med Chem Lett 2001;11:2637-41.
81. Engman L, Kandra T, Gallegos A, Williams R, Powis G. Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells. Anticancer Drug Des 2000;15(5):323-30.
82. McNaughton M, Engman L, Birmingham A, Powis G, Cotgreave IA. Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth. J Med Chem 2004;47:233-239.
83. Lee Y, Vassilakos A, Feng N, Avolio T, Jin H, Viau S, et al. Anti-proliferative and anti-tumor effects of antisense oligonucleotide GTI-2601 targeted against human thioredoxin. Anticancer Drugs 2006;17:143-54.
84. Kunkel MW, Kirkpatrick DL, Johnson JI, Powis G. Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs. Anticancer Drug Des 1997;12:659-70.
85. Bradshaw TD, Matthews CS, Cookson J, Chew EH, Shah M, Bailey K, et al. Elucidation of thioredoxin as a molecular target for antitumor quinols. Cancer Res 2005;65:3911-19.
86. Mukherjee A, Westwell AD, Bradshaw TD, Stevens MF, Carmichael J, Martin SG. Cytotoxic and antiangiogenic activity of PMX464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study. Br J Cancer 2005;92:350-8.
87. Chew EH, Matthews CS, Zhang J, McCarroll AJ, Hagen T, Stevens MF, et al. Antitumor quinols: Role of glutathione in modulating quinol-induced apoptosis and identification of putative cellular protein targets. Biochem Biophy Res Commun 2006;346:242-51.
88. Berry JM, Bradshaw TD, Fichtner I, Ren R, Schwalbe CH, Wells G, et al. Quinols as novel therapeutic agents. 2.(1) 4-(1-Arylsulfonylindol-2-yl)-4- hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents. J Med Chem 2005Jan27;48(2):639-44.
89. Jordan BF, Runquist M, Raghunand N, Gillies RJ, Tate WR, Powis G, et al. The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. Clin Cancer Res 2005;11:529-36.
90. Galmarini CM. Drug evaluation: the thioredoxin inhibitor PX-12 in the treatment of cancer. Curr Opin Investig Drugs 2006;7(12):1108-15.
91. Baker AF, Dragovich T, Tate WR, Ramanathan RK, Roe D, Hsu CH, et al. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J Lab Clin Med 2006;147:83-90.
92. Wei SJ, Botero A, Hirota K, Bradburg CM, Markovina S, Laszlo A, et al. Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation. Cancer Res 2000;60:6688-95.
93. Smart DK, Ortiz KL, Mattson D, Bradburg CM, Bisht KS, Sieck LK, et al. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res 2004;64 (18):6716-24.
94. Hintze KJ, Wald KA, Zeng H, Jeffery EH, Finley JW. Thioredoxin reductase in human hepatoma cells is transcriptionally regulated by sulforaphane and other electrophiles via an antioxidant response element. J Nutr 2003;133:2721-7.
95. Nordberg J, Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 2001;31:1287-312.
96. Watson WH, Pohl J, Montfort WR, Stuchlik O, Reed MS, Powis G, et al. Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif. J Biol Chem 2003;278:33408-15.
97. Vogt A, Tamura K, Watson S, Lazo JS. Antitumor imidazolyl disulfide IV-2 causes irreversible G(2)/M cell cycle arrest without hyperphosphorylation of cyclin-dependent kinase Cdk1. J Pharmacol Exp Ther 2000;294:1070-5.
98. Shi C, Yu L, Yang F, Yan J, Zeng H. A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines. Biochem Biophys Res Commun 2003;309:578-83.
99. Lechner S, Muller-Ladner U, Neumann E, Spöttl T, Schlottmann K, Rüschoff J, et al. Thioredoxin reductase 1 expression in colon cancer: discrepancy between in vitro and in vivo findings. Lab Invest 2003;83:1321-31.
100. Matsui M, Oshima M, Oshima H, Takaku K, Maruyama T, Yodoi J, et al. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev Biol 1996;178:179-85.
101. Clissold PM, Bicknell R. The thioredoxin-like fold: hidden domains in protein disulfide isomerases and other chaperone proteins. Bioessays 2003;25:603-11.
102. Holmgren A, Aslund F. Glutaredoxin. Methods Enzymol 1995;252:283-92.
103. Lillig CH, Lonn ME, Enoksson M, Fernandes AP, Holmgren A. Short interfering RNA-mediated silencing of glutaredoxin 2 increases the sensitivity of HeLa cells toward doxorubicin and phenylarsine oxide. Proc Natl Acad Sci U S A 2004;101:13227-32.
104. Nissom PM, Lo SL, Lo JC et al. Hcc-2, a novel mammalian ER thioredoxin that is differentially expressed in hepatocellular carcinoma. FEBS Lett 2006;580:2216-26.